Lincluden Management Ltd. Grows Holdings in Johnson & Johnson (JNJ)

Lincluden Management Ltd. raised its holdings in Johnson & Johnson (NYSE:JNJ) by 15.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 120,629 shares of the company’s stock after acquiring an additional 16,265 shares during the quarter. Johnson & Johnson comprises approximately 1.2% of Lincluden Management Ltd.’s holdings, making the stock its 17th largest position. Lincluden Management Ltd.’s holdings in Johnson & Johnson were worth $15,683,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Arbor Investment Advisors LLC lifted its stake in shares of Johnson & Johnson by 4.1% in the second quarter. Arbor Investment Advisors LLC now owns 1,798 shares of the company’s stock worth $238,000 after buying an additional 71 shares during the last quarter. Confluence Investment Management LLC lifted its stake in shares of Johnson & Johnson by 4.0% in the second quarter. Confluence Investment Management LLC now owns 1,008,691 shares of the company’s stock worth $133,440,000 after buying an additional 38,521 shares during the last quarter. Bank of Montreal Can lifted its stake in shares of Johnson & Johnson by 6.3% in the second quarter. Bank of Montreal Can now owns 7,266,065 shares of the company’s stock worth $961,226,000 after buying an additional 428,310 shares during the last quarter. Marshwinds Advisory Co. lifted its stake in shares of Johnson & Johnson by 0.8% in the second quarter. Marshwinds Advisory Co. now owns 19,341 shares of the company’s stock worth $2,559,000 after buying an additional 157 shares during the last quarter. Finally, M. Kraus & Co lifted its stake in shares of Johnson & Johnson by 0.6% in the second quarter. M. Kraus & Co now owns 43,770 shares of the company’s stock worth $5,790,000 after buying an additional 280 shares during the last quarter. Hedge funds and other institutional investors own 65.79% of the company’s stock.

Johnson & Johnson (NYSE JNJ) traded down $2.34 on Friday, hitting $137.68. 9,197,500 shares of the stock traded hands, compared to its average volume of 7,360,000. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a fifty-two week low of $112.62 and a fifty-two week high of $148.32. The company has a market cap of $369,880.00, a price-to-earnings ratio of 353.03, a price-to-earnings-growth ratio of 2.47 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The business had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same quarter in the prior year, the firm earned $1.58 EPS. The firm’s quarterly revenue was up 11.5% compared to the same quarter last year. sell-side analysts predict that Johnson & Johnson will post 8.11 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.44%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s payout ratio is 861.54%.

A number of analysts have recently weighed in on JNJ shares. Wells Fargo & Co upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $140.00 to $149.00 in a research note on Monday, October 9th. Jefferies Group upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $145.00 to $157.00 in a research note on Wednesday, October 11th. Vetr cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $129.62 price objective for the company. in a research note on Friday, October 13th. Leerink Swann reaffirmed an “outperform” rating and set a $165.00 target price (up previously from $150.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Finally, Royal Bank of Canada boosted their target price on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $146.16.

TRADEMARK VIOLATION WARNING: “Lincluden Management Ltd. Grows Holdings in Johnson & Johnson (JNJ)” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://stocknewstimes.com/2018/02/04/johnson-johnson-jnj-holdings-lifted-by-lincluden-management-ltd.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.